A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference

Blood. 2018 Aug 9;132(6):670-672. doi: 10.1182/blood-2018-05-848986. Epub 2018 Jun 11.

Authors

John R Mills¹, Mindy C Kohlhagen¹, Maria A V Willrich¹, Taxiarchis Kourelis², Angela Dispenzieri^{1

2}, David L Murray¹

Affiliations

¹ Department of Laboratory Medicine and Pathology and.
² Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

PMID: 29891533
DOI: 10.1182/blood-2018-05-848986

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Blood Protein Electrophoresis / methods
Drug Monitoring / methods*
False Positive Reactions
Humans
Immunoglobulin G / blood*
Immunoglobulin kappa-Chains / blood*
Mass Spectrometry / methods*
Molecular Weight
Multiple Myeloma / blood
Multiple Myeloma / drug therapy*
Myeloma Proteins / analysis*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immunoglobulin G
Immunoglobulin kappa-Chains
Myeloma Proteins
elotuzumab
daratumumab
isatuximab